High Titer Transient Expression with GS Discovery® platform
Accelerate your candidate screening with the GS Discovery® platform– the high-performance mammalian transient expression platform designed for speed and scalability.
Move from DNA to protein in weeks, generating the high-titer samples you need for rapid lead selection without the timelines of stable cell line development. By leveraging a transient expression system that mirrors our commercial CHO GS Xceed® cell line, we ensure your transient antibody expression results remain consistent and predictable as you scale.
Shorten your discovery phase and de-risk your transition to manufacturing with the industry’s most reliable mammalian transient expression solution.
Once transfected, the cells are cultivated in specialized, chemically defined media optimized for rapid growth and high secretion. Our mammalian transient expression protocols are engineered to produce milligram-to-gram quantities of your protein in as little as 7 to 14 days, providing the speed necessary for high-throughput screening.
Contact our technical experts for more information.
Because our transient expression platform utilizes the same CHO cell lineage as our commercial GS Gene Expression System® technology platform, the data you gather during discovery is highly predictive of future performance. This alignment minimizes technical risk when you eventually transition your winning candidate from a temporary transient setup to a permanent, stable manufacturing cell line.
Gain insight into how optimized transient expression workflows can support fast, early‑stage evaluation across diverse therapeutic protein formats. This white paper outlines how the GS Discovery® transient expression platform leverages established GS® expression system tools to generate high‑quality material quickly and streamline progression into later development.
Contact our technical experts for more information.
With our Lonza in Your Lab® service, you can access to the GS Discovery® system via a license to drive the progression of your early stage projects. With the GS® technology platform, there is no need to switch expression systems later in development simply use the same tools from discovery phase, through development, to commercial production.
Contact our technical experts for more information.
Ask the Experts in Expression
The GS Discovery® transient expression system accelerates early screening, compared to standard transient workflows, by enabling rapid DNA to protein turnaround using optimized mammalian transient expression workflows. By combining GS Xceed® CHO cells with GS piggyBac® technology, the platform delivers high titer material in days rather than months, allowing teams to quickly assess candidate developability, potency and stability. Compared to traditional transient methods, this helps researchers make faster, data driven decisions before committing to stable cell line development.
A transient expression system is designed for high speed. Unlike stable cell line development, which can take months, transient expression allows you to move from DNA transfection to purified protein in as little as 10 to 14 days. This rapid turnaround is essential for high-throughput screening and early-stage lead optimization.
Our transient antibody expression protocols are highly scalable, allowing you to generate anywhere from milligram to gram quantities of your target molecule. This flexibility allows researchers to produce enough material for everything from initial binding assays to advanced in vivo toxicology studies without the commitment of building a stable cell line.
Consistency is a core benefit of the GS Discovery® transient expression platform. Because we use the same CHO host cell lineage and chemically defined media across both our transient and stable systems, the characteristics of your protein remain consistent. This reduces technical risk, ensuring that the "winner" you identify in discovery will behave the same way during large-scale commercial manufacturing.
Yes. The GS Discovery® transient expression platform is engineered to support a broad range of therapeutic formats, including complex antibodies and next generation biologics. With optimized mammalian transient expression processes and high performance CHO cells, the system can deliver robust titers even for challenging molecules, offering a reliable pathway to quickly generate high quality material for functional testing and lead selection.
Sign up. Stay up-to-date.